Iodixanol in cardioangiography. A double-blind parallel comparison between iodixanol 320 mg I/ml and ioxaglate 320 mg...

Area of Science:

• Radiology
• Cardiology
• Pharmacology

Background:

• Cardioangiography utilizes contrast media to visualize cardiac structures.
• Non-ionic, dimeric contrast agents offer improved safety profiles.
• Iodixanol (Visipaque) and ioxaglate (Hexabrix) are commonly used contrast agents.

Purpose of the Study:

• To compare the safety and efficacy of iodixanol versus ioxaglate in cardioangiography.
• To evaluate patient tolerability and effects on renal function.
• To assess radiographic performance of both contrast media.

Main Methods:

• A prospective study involving 102 patients with normal renal function.
• Randomized comparison of iodixanol 320 mg I/ml and ioxaglate 320 mg I/ml.
• Monitoring of adverse events, patient discomfort, vital signs, and renal function parameters.

Main Results:

• Both contrast media exhibited minor effects on renal function.
• Iodixanol group reported significantly fewer adverse events and less discomfort.
• Patients receiving iodixanol had a lower increase in heart rate post-procedure.
• Radiographic efficacy was comparable and good for both agents.

Conclusions:

• Iodixanol 320 mg I/ml is a safe and effective contrast medium for cardioangiography.
• Iodixanol offers superior tolerability and a better safety profile compared to ioxaglate.
• The choice of contrast agent can impact patient comfort and adverse event rates.